RA
PRAX icon

Royce & Associates’s Praxis Precision Medicines PRAX Stock Holding History

Royce & Associates’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Buy
+6,544
New +$2.07M 0.02% 598

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Royce & Associates's PRAX Position: Q2 2026 in Review

Royce & Associates opened a new position in Praxis Precision Medicines (PRAX) in Q2 2026: 6,544 shares worth $2.19M. The stake represents 0.02% of the portfolio and ranks #598 among its holdings.

309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Royce & Associates held 6,544 shares of Praxis Precision Medicines worth $2.19M as of Q2 2026.
  • Praxis Precision Medicines was a new Royce & Associates position in Q2 2026.
  • Praxis Precision Medicines made up 0.02% of Royce & Associates's portfolio in Q2 2026, its #598 holding.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.